Successful treatment with rituximab in a patient with TTP secondary to severe ANCA-associated vasculitis.
We report a case of thrombotic thrombocytopenic purpura (TTP) secondary to antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis treated by rituximab. TTP secondary to ANCA-associated vasculitis is very rare and has a high mortality rate. We employed rituximab and successfully treated TTP secondary to ANCA-associated vasculitis, because standard therapies, such as steroid therapy, intravenous pulse cyclophosphamide, and repeated plasma exchange (PE), did not suppress her disease activity. This is the first report to suggest that rituximab can achieve complete remission of TTP secondary to ANCA-associated vasculitis.
Asamiya
Yukari
Y
Department of Medicine, Kidney Center, Tokyo Women's Medical University.
Moriyama
Takahito
T
Takano
Mari
M
Iwasaki
Chihiro
C
Kimura
Kazuo
K
Ando
Yukako
Y
Aoki
Akiko
A
Kikuchi
Kan
K
Takei
Takashi
T
Uchida
Keiko
K
Nitta
Kosaku
K
D056648:Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis / Q000150:complications* / Q000175:diagnosis / Q000188:drug therapy*; D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008875:Middle Aged; D011697:Purpura, Thrombotic Thrombocytopenic / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology*; D000069283:Rituximab; D012720:Severity of Illness Index; D016896:Treatment Outcome
D058846:Antibodies, Monoclonal, Murine-Derived; D000069283:Rituximab